Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GO 2068/1-1)
Received: 3 January 2020
Accepted: 6 February 2020
First Online: 14 February 2020
Ethics approval and consent to participate
: The trial protocol was approved by the responsible lead ethics committee of the Landesärtzekammer Hessen, Hanauer Landstr. 152, 60314 Frankfurt am Main, Germany, responsible for the Krankenhaus Nordwest Frankfurt- UCT (University Cancer Center) on the 11th January 2019 under the identification number FF 108/2019. An amendment of the study was approved by the responsible lead ethics committee on 26th July 2019, Version 1.4. The trial has been registered on the ExternalRef removed website under the identification number NCT03673072 ExternalRef removed. The GAIN study complies with the Declaration of Helsinki rules, the principles of Good Clinical Practice guidelines and the Data Protection Act. The study will also be carried out in compliance to local legal and regulatory requirements. For each patient to be enrolled into the study, obtaining written informed consent prior to trial inclusion is essential.
: Not applicable.
: The authors declare that they have no competing interests.